Accordingly, ELN (European LeukemiaNet) recommended in 2010 rapid evaluation of the mutational status of NPM1, FLT3 and CEBPa in normal karyotype AML patients to better characterize their prognosis risk and define the best therapeutic option [7]. The gene discussed is NPM1; the disease is acute myeloid leukemia.